Aclarion, Inc. (ACON) AI Stock Analysis

Aclarion, Inc. is a healthcare technology company based in San Mateo, California, specializing in the development of advanced software applications for magnetic resonance spectroscopy (MRS). The company's flagship product, the NOCISCAN-LS Post-Processor suite, includes NOCICALC-LS, which processes disc MRS data to calculate levels of degenerative pain biomarkers. Additionally, Aclarion offers NOCIGRAM-LS, a clinical decision support software designed to aid healthcare professionals in interpreting MRS results and making informed treatment decisions. Formerly known as Nocimed, Inc., the company rebranded in December 2021 to expand its focus on medical diagnostics and pain management in degenerative disc disease.

Aclarion reported revenue of $75,730 in FY2025, an increase of 65.6% from $45,724 in FY2024, after previously generating $75,404 in FY2023. Between FY2020 and FY2025, revenue expanded at a five-year CAGR of 9.3%. Profit margins remained negative, with gross margin dropping to -291.3% in FY2025 from -183.8% in FY2024, and operating margin recorded at -9312.5%. Net income in FY2025 was -$7.2M, representing an EPS of -$19.52. For the trailing twelve months ending June 30, 2026, revenue totaled $83,769, with quarterly revenue growth rising 30.5% year-over-year and operating margin reaching -11503.2%.

As of June 30, 2026, Aclarion held $16.3M in cash and short-term investments, supporting total assets of $18.0M and shareholders' equity of $17.0M. The company reported a current ratio of 16.20. For FY2025, operating cash flow was -$7.2M and free cash flow was -$7.2M. Cash utilization during FY2025 included capital expenditures of $21,526, share buybacks of $1.2M, and dividends paid of $5.42B.

Aclarion carries a market capitalization of $5.3M and an enterprise value of -$8.7M. The stock trades at a price-to-sales multiple of 63.7x and an EV to revenue multiple of 79.6x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its price-to-book multiple is 0.4x. Shares closed at $1.85 on October 16, 2026, down 78.7% over the trailing 12 months, trailing the S&P 500 (SPY) return of 16.8%.

Wall Street coverage consists of 1 Strong Buy rating, 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The mean price target is $7.62, representing a 312.2% premium over the last close of $1.85. For the fiscal year ending December 31, 2026, the consensus estimate projects revenue of $109,470 and an EPS of -$4.51. For the following fiscal year, 1 analyst projects revenue of $245,180 and an EPS of -$5.47. Aclarion has beaten EPS estimates in 1 of the last 4 quarters, with its next earnings date scheduled for November 11, 2026.

This page is an AI-written research summary of Aclarion, Inc. (ACON). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACON income statement, ACON balance sheet, ACON key metrics, ACON analyst forecast, ACON chart. See the ACON stock overview for the latest quote and news.